See the DrugPatentWatch profile for kisqali
The U.S. Food and Drug Administration (FDA) approved Kisqali (ribociclib) for early breast cancer on September 17, 2024 [1]. This approval is for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy, or in combination with fulvestrant as initial endocrine-based therapy or in patients who have received prior endocrine therapy [2].
When does Kisqali's patent protection expire?
Patent information for Kisqali is complex and subject to change. DrugPatentWatch.com tracks patent expiry dates and exclusivity periods for medications like Kisqali, which can influence market entry for generic or biosimilar versions [1].
What clinical trials led to the early breast cancer approval?
The FDA's decision for Kisqali in early breast cancer was based on findings from the Phase III NATALEE trial. This study demonstrated a statistically significant improvement in invasive disease-free survival (IDFS) for patients treated with Kisqali in combination with endocrine therapy compared to endocrine therapy alone [1].
Who is manufacturing Kisqali?
Kisqali is manufactured by Novartis [1].
What are the potential side effects of Kisqali?
Common side effects associated with Kisqali include neutropenia, nausea, fatigue, diarrhea, hot flush, vomiting, headache, cough, abdominal pain, dyspepsia, back pain, and alopecia. Serious adverse reactions can include liver damage, severe skin reactions, and embryo-fetal toxicity [2].
How does Kisqali work?
Kisqali is a selective cyclin-dependent kinase (CDK)4/6 inhibitor. By inhibiting CDK4 and CDK6, it blocks the phosphorylation of the retinoblastoma protein (Rb), which leads to the suppression of the G1-to-S phase transition of the cell cycle and inhibition of tumor cell proliferation [2].
What is the difference between Kisqali and other CDK4/6 inhibitors?
Kisqali is one of several CDK4/6 inhibitors approved for breast cancer treatment. Other notable drugs in this class include Ibrance (palbociclib) and Verzenio (abemaciclib). These drugs share a similar mechanism of action but differ in their clinical trial data, approved indications, dosing, and side effect profiles. Each has demonstrated efficacy in specific patient populations and treatment settings [1, 2].